Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of Pirtobrutinib Formulations
NCT06258174Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pirtobrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose, Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration at 168 hours and 6 more. Started Sep 2021; status: completed.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06258174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258174.